Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MY008211A in Primary IgA Nephropathy
NCT06687174Phase 2Not yet recruiting
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd.
- Start
- Dec 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MY-008 in IgA nephropathy (IgAN), sponsored by Wuhan Createrna Science and Technology Co., Ltd.. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
MY-008
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT06687174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06687174.